Cristiano D'Amico
Regional Head Italy at OncoSil Medical- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
-
Inglese Professional working proficiency
Topline Score
Bio
Credentials
-
HMX PRO Immunology--Immuno-Oncology
Harvard Medical SchoolNov, 2020- Sep, 2024 -
HMX Fundamentals - Immunology
Harvard Medical SchoolSep, 2020- Sep, 2024 -
London Pancreas Workoshop 2020
Barts Cancer InstituteSep, 2020- Sep, 2024 -
Anatomy of the Chest, Abdomen and Pelvis
Coursera Course CertificatesApr, 2020- Sep, 2024 -
Englishtown course advanced
EF EnglishtownMar, 2014- Sep, 2024 -
Corso Primo Soccorso e CPR teorico
Ospedale Luigi Sacco - Azienda Ospedaliera Polo UniversitarioMar, 2010- Sep, 2024 -
Business English Course 6
GlobalEnglishAug, 2010- Sep, 2024 -
Personal Trainer CFT I ISSA
ISSA EuropeDec, 2012- Sep, 2024
Experience
-
OncoSil Medical
-
Australia
-
Medical Equipment Manufacturing
-
1 - 100 Employee
-
Regional Head Italy
-
Oct 2020 - Present
Introducing the new breakthrough medical device Oncosil in the Italian market. Oncosil is based on the radionuclide Fosforus 32 tecnology and is indicated for the treatment of LAPC (Local Advanced Pancreatic Cancer) in combination with gemcitabine-based chemio. Introducing the new breakthrough medical device Oncosil in the Italian market. Oncosil is based on the radionuclide Fosforus 32 tecnology and is indicated for the treatment of LAPC (Local Advanced Pancreatic Cancer) in combination with gemcitabine-based chemio.
-
-
-
Sirtex Medical Limited
-
United States
-
Medical Equipment Manufacturing
-
200 - 300 Employee
-
Key Account Manager Center-South Italy
-
Jun 2016 - Oct 2020
Key Responsibility and Achievements:• Analysis of market opportunities and support key centers in referral flow from advisor (oncologist, hepatologist, surgeon) to interventional radiologist centers within SIR-Spheres resin microsphere.• Networking and Competitor analysis • Mapping and opening of new centers and training IRs and MedNucs. • Developed training course and educated nuclear medicine staff to specifically manage SIR-Sphere resin microsphere, dosimetry software, management of safety from exposure to ionizing radiation.• Support to IRs end MedNucs during both angiographic and nuclear procedure• Speaker in department hospital meeting to share SIR-Sphere resin microsphere procedure• Implemented awareness program on diseases management through tailored educational program and platform (Webinar meetings)• Support the center in budget funding and payment flow• Developed Pharmaeconomic toll (HTA) in collaboration with Institutional parties• Sales Council Advisor member for ItalyREPORTING/RELATIONSHIP:• Report to the National Sales Manager Italia• Strong cooperation with Medical, Marketing and Finance division Show less
-
-
Oncology Specialist
-
May 2015 - May 2016
Oncology Specialist Lazio, Campania, Puglia, Sicilia Product: SIR-Spheres microspheres Active Implantable Medical Device SCOPE: I analyse the market opportunities independently and driving referrals from advisor (surgeon, oncologist and hepatologist) to treating interventional radiologist within SIRSpheres Y90 resin microspheres. Daily work Customer- Market- and Competitor analysis. I organize and carry out medical educational events as well as participating in congresses and local events. REPORTING RELATIONSHIP: I report to the Oncologist Specialist Manager Europe Strong cooperation with Key-Account Manager Show less
-
-
-
Astellas Pharma
-
Japan
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Urology/Oncology Specialist
-
Nov 2013 - Apr 2015
11/2013 – present ASTELLAS PHARMA S.p.A. Uro-oncology Specialist Lazio Products:Enzalutamide (mCRPC) X-Tandi Leuprorelin (CAP) Eligard • Premarketing activity and new drug Enzalutamide launch. • Cross-functional activity with Market Access and Field Medical Liaison. • International Booth Professional activity (EAU 14, EAU 15, PROSCA 15) • Accomplished the insertion of Xtandi in PTOR. • Strong relationship with KOLs/ Units Directors and Local Working Group in Oncology-Focus on Prostate Cancer Show less
-
-
-
-
Oncology Specialist
-
Oct 2009 - Oct 2013
2009 – 2013 AMGEN SpA Oncology Specialist Lazio, Umbria. Products: Panitumomab (mCRC) Vectibix Darbepoietina (ESA) Aranesp • Scientific communication to address haematologists and oncologists on the support therapy and treatment mCRC. • Cross-functional activity with Market Access and Field Medical Liaison. • Promoted and presented drugs with Ipad Software Agnitio • Strong relationship with Lazio oncology, radiotherapist oncology and hematology KOL 2009 – 2013 AMGEN SpA Oncology Specialist Lazio, Umbria. Products: Panitumomab (mCRC) Vectibix Darbepoietina (ESA) Aranesp • Scientific communication to address haematologists and oncologists on the support therapy and treatment mCRC. • Cross-functional activity with Market Access and Field Medical Liaison. • Promoted and presented drugs with Ipad Software Agnitio • Strong relationship with Lazio oncology, radiotherapist oncology and hematology KOL
-
-
-
Bayer HealthCare
-
United States
-
Product Specialist
-
May 2007 - Sep 2009
2006 – 2009 BAYER HEALTHCARE BAYER SCHERING PHARMA 2006 – 03/09 Onco-Hematology Specialist Center Italy Products: IbritumomabTiuxetan(NHL)Zevalin 09/2006 – 10/2009 Bayer S.p.A. Bayer Schering Pharma Field Specialist Onco-Ematologia Alentuzumab (LLC) MabCampath Fludarabin (LLC) Fludara • Specialist in radio-immunotherapy. • Launched Zevalin in Central Italian market • Interacted and presented drug between nuclear medicine physicians and important hospital centers for oncology/hematology therapy • Accomplished the insertion of Zevalin (innovative radioimmunotherapeutic drug) in PTO • Promoted and presented Zevalin to create hospital budget for this drug. Achieved treatment use in eight hospitals in Center Italy. • Developed, managed and organized 2 citywide and 14 hospital meetings to present Zevalin to hematologists, pharmacist, and hospital administrators. Show less
-
-
-
Schering AG
-
Germany
-
Pharmaceutical Manufacturing
-
1 - 100 Employee
-
Product Specialist
-
May 2000 - Apr 2007
2000 – 06 SCHERING S.P.A. Sept. 05 Onco-Hematology and Nuclear Medicine Specialist Center and Southern Italy Products: Ibritumomab Tiuxetan-yttrium 90 (NHL) Zevalin ▪ Presented Zevalin to hematologist and nuclear medicine physicians ▪ Developed training course and educated nuclear medicine staff to specifically labeling of new drug Zevalin plus radio nucleotide yttrium90 ▪ Promoted and organized meeting with KOP radio-chemistry physicians to calibrated and control medical instruments to use yttrium90 ▪ Developed and planned several hospital meetings to present Zevalin to hematologists, pharmacist, and hospital administrators. 00 – Aug 05 Product Specialist Urology/Andrology Lazio Products: Acetate Ciproterone (Prostate Cancer) Androcur Testosterone (androgenic dysfunction) Testogel, Proviron, Testoviron. • Sales: Area assigned first in Italy for Market share increase. • Strong relationship with Lazio urology and andrology KOL. • Field force Andrology e uro-oncology training and market competitors’ analysis. • Clinical monitor in observational studies “QuaBios”, Q10 e Q10f Show less
-
-
-
lusofarmaco
-
Italy
-
Pharmaceutical Manufacturing
-
1 - 100 Employee
-
Salesrep
-
May 1997 - Apr 2000
1997 – 2000I.L.F.I. ISTITUTO LUSOFARMACO D’ITALIA Sales representative Rome • I have dealt with many therapeutic areas: cardiology, urology. 1997 – 2000I.L.F.I. ISTITUTO LUSOFARMACO D’ITALIA Sales representative Rome • I have dealt with many therapeutic areas: cardiology, urology.
-
-
Education
-
1991 - 1997
Università degli Studi di Roma la sapienza
Scienze Biologiche, M.F.S. -
Liceo Francesco d'Assisi
-
Liceo Francesco d'Assisi
-
Università di Roma Tor Vergata
Community
